TP53 and B-cell chronic lymphocytic leukemia: Idelalisib in combination with an anti-CD20 monoclonal antibody (rituximab or ofatumumab) is also indicated for the treatment of relapsed/refractory CLL and as first-line therapy in patients with del(17p)/TP53 mutations who are not candidates for other therapies [29].